DACLERAD Trademark

Trademark Overview


On Thursday, January 21, 2021, a trademark application was filed for DACLERAD with the United States Patent and Trademark Office. The USPTO has given the DACLERAD trademark a serial number of 90480644. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Wednesday, December 11, 2024. This trademark is owned by Bristol-Myers Squibb Company. The DACLERAD trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use for immunotherapy, including T Cell therapy; Pharmaceutical p...
daclerad

General Information


Serial Number90480644
Word MarkDACLERAD
Filing DateThursday, January 21, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateWednesday, December 11, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 22, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use for immunotherapy, including T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use
Translation of Words in MarkThe wording "DACLERAD" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, April 22, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Monday, January 25, 2021NEW APPLICATION ENTERED
Thursday, April 22, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 11, 2021ASSIGNED TO EXAMINER
Wednesday, May 19, 2021NON-FINAL ACTION WRITTEN
Wednesday, May 19, 2021NON-FINAL ACTION E-MAILED
Wednesday, May 19, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 16, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, November 16, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 17, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 27, 2022FINAL REFUSAL WRITTEN
Thursday, January 27, 2022FINAL REFUSAL E-MAILED
Thursday, January 27, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, July 19, 2022EXAMINERS AMENDMENT -WRITTEN
Tuesday, July 19, 2022EXAMINERS AMENDMENT E-MAILED
Tuesday, July 19, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, July 19, 2022EXAMINER'S AMENDMENT ENTERED
Friday, October 14, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 2, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 22, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 22, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 17, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, July 10, 2023SOU TEAS EXTENSION RECEIVED
Monday, July 10, 2023SOU EXTENSION 1 FILED
Monday, July 10, 2023SOU EXTENSION 1 GRANTED
Wednesday, July 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, January 2, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, January 2, 2024SOU EXTENSION 2 FILED
Tuesday, January 2, 2024SOU EXTENSION 2 GRANTED
Thursday, January 4, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 26, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, June 26, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 26, 2024SOU EXTENSION 3 GRANTED
Wednesday, June 26, 2024SOU EXTENSION 3 FILED
Wednesday, December 11, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, December 11, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 11, 2024SOU EXTENSION 4 FILED
Wednesday, December 11, 2024SOU EXTENSION 4 GRANTED